AI Article Synopsis
- Tralokinumab, both as a standalone treatment and combined with topical corticosteroids, showed significant effectiveness in treating moderate-to-severe atopic dermatitis over a 52-week period in phase 3 trials.
- The study analyzed early changes in patient-reported outcomes (PROs) from three trials (ECZTRA 1, 2, and 3), demonstrating that patients on tralokinumab experienced noticeable improvements in itch and sleep quality within the first few weeks compared to those on placebo.
- Overall, the results indicate that tralokinumab provides meaningful relief from atopic dermatitis symptoms, which is a primary concern for patients, highlighting its potential benefits.
Article Abstract
Background: Tralokinumab, as monotherapy or in combination with topical corticosteroids (TCS), has exhibited marked efficacy through 52 weeks in phase 3 trials of adults with moderate-to-severe atopic dermatitis and additional efficacy in a long-term extension trial. Early changes in patient-reported symptoms have not been communicated.
Objective: To evaluate early changes in patient-reported outcomes (PROs) across the ECZTRA 1, 2, and 3 tralokinumab trials.
Methods: Monotherapy data (ECZTRA 1 + 2) was pooled; ECZTRA 3 evaluated tralokinumab plus optional TCS. The PROs were assessed through the trials.
Results: A total of 1596 and 380 patients were randomized in ECZTRA 1 and 2 and ECZTRA 3, respectively. Baseline demographics and clinical characteristics were similar between groups. Early separation from placebo was observed in percentage improvement in worst average daily pruritus numerical rating score (NRS) (week 1, ECZTRA 1 + 2; week 2, ECZTRA 3) and from day 2 in ECZTRA 1 and 2 daily data. More tralokinumab-treated patients achieved clinically meaningful improvements (≥ 4 points) in NRS by week 2 (ECZTRA 1 + 2) or week 3 (ECZTRA 3) vs placebo. Improvements in eczema-related sleep NRS were seen within 2 weeks (week 1, ECZTRA 1 + 2; week 2, ECZTRA 3), supported by similar improvements in other sleep measures. Meaningful changes in Dermatology Life Quality Index were observed from week 2 (ECZTRA 1 + 2). Results were supported by numerical differences from placebo in Patient-Oriented Eczema Measure total score (week 2, both data sets).
Conclusion: Tralokinumab with or without TCS exhibited early and clinically meaningful improvements vs placebo in several PROs, which may be beneficial to patients because atopic dermatitis symptom relief is a key treatment concern for patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.anai.2022.07.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis.
Br J Dermatol
December 2024
Department of Dermatology, Oregon Health & Science University, Portland, OR, USA.
Background: Approved tralokinumab maintenance dosing regimens for treatment of moderate-to-severe atopic dermatitis (AD) include 300 mg every two weeks (Q2W) and every four weeks (Q4W), that clinicians may consider for patients who achieved clear or almost clear skin at Week 16 with initial Q2W dosing.
Objectives: To identify predictive factors associated with maintained response after switching to tralokinumab Q4W, evaluate recapture of treatment response after relapse on Q4W, and assess treatment-emergent immunogenicity with tralokinumab Q4W.
Methods: These post hoc analyses utilized machine learning to identify predictive factors for maintained treatment response at Week 52 using data from the Week 16 responder population (ie, patients who met Investigator's Global Assessment of clear/almost clear skin [IGA 0/1] and/or ≥75% improvement in Eczema Area and Severity Index (EASI-75) at Week 16 with tralokinumab Q2W monotherapy) of the phase 3 ECZTRA 1 and 2 trials.
Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis.
Dermatol Ther (Heidelb)
April 2024
Hospital Universitari Germans Trias I Pujol, UAB, IGTP, Badalona, Spain.
Article Synopsis
- - The study compares the efficacy of two treatments for moderate-to-severe atopic dermatitis: tralokinumab and dupilumab, both used with topical corticosteroids, without any direct head-to-head trials being conducted.
- - An indirect comparison analysis was performed using patient data from past trials, measuring improvements in various clinical response metrics at week 32, including Eczema Area and Severity Index (EASI) and quality of life assessments.
- - Results showed that both treatments had similar effectiveness overall; however, tralokinumab demonstrated a statistically significant greater improvement in the Dermatology Life Quality Index compared to dupilumab, indicating a preference for tralokinumab in enhancing quality of life.
Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years.
Allergy
June 2024
Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Background: Tralokinumab is a monoclonal antibody that specifically neutralizes interleukin (IL)-13, a key driver of skin inflammation and barrier abnormalities in atopic dermatitis (AD). This study evaluated early and 2-year impacts of IL-13 neutralization on skin and serum biomarkers following tralokinumab treatment in adults with moderate-to-severe AD.
Methods: Skin biopsies and blood samples were evaluated from a subset of patients enrolled in the Phase 3 ECZTRA 1 (NCT03131648) and the long-term extension ECZTEND (NCT03587805) trials.
Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1.
Am J Clin Dermatol
January 2024
Department of Dermatology and Allergology, Ludwig-Maximilian University, Frauenlobstrasse 9-11, 80337, Munich, Germany.
Article Synopsis
- The study aimed to evaluate the effects of tralokinumab, a treatment for chronic moderate-to-severe atopic dermatitis, compared to a placebo on various clinically important outcomes in patients not reaching the main goal of clear skin at week 16.
- A total of 1328 patients from two phase III trials, ECZTRA 1 and 2, were analyzed, focusing on improvements in eczema severity and patient-reported symptoms like itch and quality of life.
- Results showed that significantly more patients using tralokinumab attained meaningful improvements in eczema severity (EASI-50), itch ratings, and quality of life compared to those on placebo, indicating tralokinumab's potential benefits beyond just achieving clear skin.
Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials.
Am J Clin Dermatol
November 2023
Department of Dermatology and Allergy, Ludwig Maximilian University of Munich, Munich, Germany.
Background: Two phase III trials, ECZTRA 1 and 2, confirmed the efficacy and safety of tralokinumab versus placebo in adults with moderate-to-severe atopic dermatitis (AD). To further explore the long-term efficacy of tralokinumab for AD, a pooled analysis of these trials was conducted.
Methods: ECZTRA 1 and 2 patients (n = 1596 total) were randomized to tralokinumab 300 mg or placebo every 2 weeks (q2w) over 16 weeks.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!